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Vitamin D is the main hormone of bone metabolism. However, the ubiquitary nature of vitamin D receptor (VDR) suggests
potential for widespread effects, which has led to new research exploring the effects of vitamin D on a variety of tissues, especially
in the skeletal muscle. In vitro studies have shown that the active form of vitamin D, calcitriol, acts in myocytes through genomic
effects involving VDR activation in the cell nucleus to drive cellular differentiation and proliferation. A putative transmembrane
receptor may be responsible for nongenomic effects leading to rapid influx of calcium within muscle cells. Hypovitaminosis D is
consistently associated with decrease in muscle function and performance and increase in disability. On the contrary, vitamin D
supplementation has been shown to improve muscle strength and gait in different settings, especially in elderly patients. Despite
some controversies in the interpretation of meta-analysis, a reduced risk of falls has been attributed to vitamin D supplementation
due to direct effects on muscle cells. Finally, a low vitamin D status is consistently associated with the frail phenotype. This is why
many authorities recommend vitamin D supplementation in the frail patient.
1. Introduction
Vitamin D is the main hormone regulating calcium phos-
phate homeostasis andmineral bonemetabolism.Thediscov-
ery that a variety of tissues can express vitamin D receptor
(VDR) has opened new ways of research related to vitamin
D biological effects and molecular pathways [1–3]. There is
evidence that vitamin D is implicated in the regulation of the
immune system, the cardiovascular system, oncogenesis [4],
and cognitive functions [5].
Loss of muscle mass and frailty are prevalent in many
chronic diseases such as chronic obstructive pulmonary
disease, cardiac insufficiency, cancer, and chronic kidney
disease (CKD) [6].
Vitamin D deficiency is indeed extremely frequent in
the above diseases. More than 3 decades ago, the clinical
observation that patients with rickets and osteomalacia dis-
played proximal myopathy suggested a direct link between
hypovitaminosis D andmuscle function [7]. Recent evidence
has confirmed that vitamin D may modulate muscle growth.
In this review, wewill specifically address the effect of vitamin
D on skeletal muscles and its clinical implications, especially
frailty and the risk of fall.
2. Methods
This is a review article not intended to meet the full range
of criteria required for a systematic review. However, we
used a rigorous methodology for the selection of the material
presented here. InOctober 2014, we performed a comprehen-
sive literature search in the bibliographic database “Pubmed,”
looking at studies discussing the following topics: “hypovita-
minosis D and physical performance: observational studies,”
“can vitamin D supplementation improve muscle function?,”
“relationship between vitamin D status, muscle and falls,”
and “link between vitamin D and frailty.” The study period
considered was from January 1, 2000, to September 30, 2014.
Keywords used were “vitamin D,” “muscle,” “strength,” “fall,”
“frailty,” “risk,” “chronic kidney disease,” “supplementation,”
“randomized controlled trial,” “review,” “systematic review,”
and “meta analysis.” Only articles in English were considered.
From the studies identified in this way, we selected only
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observational trials, randomized control trials (RCTs), and
meta-analysis. Case reports and series were excluded. In stud-
ies testing vitamin D supplementation, the dose of vitamin D
should have been specified, physical performance/gait should
have been reported by objective measurements, and blood
level of vitamin D should have been reported. In studies
regarding frailty, the terminology of frailty should have been
defined by objective criteria. Finally, we did not include
the totality of studies meeting the above criteria, in order
to prevent redundancies. Studies confirming results from
previous relevant studies and providing similar conclusions
were voluntarily not cited.
3. Vitamin D Metabolism
Vitamin D metabolism is orchestrated by the skin, the
liver, and the kidney. The role of sun exposure is instru-
mental since UVB-induced vitamin D3 production in the
skin accounts for 80–90% of vitamin D formation, whereas
nutritional intake (fatty fish, eggs, fortified milk, and plants)
only accounts for 10–20% of vitamin D3 provision. UVB
converts 7-dehydrocholesterol to previtamin D which is then
converted to cholecalciferol (or vitamin D3). Cholecalciferol
subsequently binds to vitamin D binding globulin and this
complex is transported to the liver where it is hydroxylated in
25-hydroxyvitaminD3 (or 25(OH)D3), themajor circulating
form. 25-Hydroxyvitamin D3 undergoes a final hydroxy-
lation in the kidney proximal tubule in order to produce
1,25 dihydroxyvitamin D3 or calcitriol, the biologically active
form [8].The 1-hydroxylation is stimulated by the parathyroid
hormone (PTH) and inhibited by the Fibroblast Growth
Factor 23 (FGF-23). Calcitriol interacts with vitaminD recep-
tor (VDR) in the cell nucleus to mediate biological effects
through activation of calcium channels. Vitamin D synthesis
depends on environmental factors such as sunlight exposure
and sun cream application [9] and biologic factors such as
skin’s pigmentation and kidney function. In elderly people,
dietary vitamin D (vitamin D2 from plants and vitamin D3
from animals) may become the major source of vitamin D3
because of reduced 7-dehydrocholesterol concentration [10]
and impaired hydroxylation in the liver and the kidney [11].
This is why the relevance of vitamin D status is highlighted in
this population. This is particularly true for the elderly frail
patient clinically characterized by a lownutritional intake and
muscle loss. Whether vitamin D deficiency may aggravate
muscle function and frailty is thus a very important question.
4. Vitamin D Deficiency and Insufficiency
Because of unregulated hydroxylation by the liver, 25-
hydroxyvitamin D is used as the marker of vitamin D
status. Low levels of serum vitamin D (25-hydroxyvitamin
D) may define vitamin D deficiency versus insufficiency
[12]. However, the definitions of low levels of vitamin D
vary among authors and nutritional societies/authorities. For
some authors, vitamin D deficiency is the level below which
osteomalacia may appear [13]. In general, this occurs at a
concentration below 25 nmol/L [12]. Vitamin D insufficiency
may be defined as the level below which PTH begins to rise.
Depending on the studies, this level may vary from 25 to
75 nmol/L. Another definition is only based on serum con-
centration thresholds without considering biological or clin-
ical abnormalities [14]. According to this definition, vitamin
D status may be divided into 4 group levels: severe deficiency
defined by a concentration of less than 27.5 nmol/L, deficiency
between 27.5 and 49.9 nmol/L, insufficiency between 50 and
75 nmol/L, and optimal above 75 nmol/L [15, 16]. Differences
of definitions between authors may explain, at least in part,
conflicting resulting from meta-analysis addressing vitamin
D status and outcomes. Vitamin D deficiency/insufficiency
is highly prevalent but the magnitude of hypovitaminosis D
may vary depending on the population studied and regional
and seasonal considerations. We will only comment on
examples of prevalence in the elderly population. Among
healthy elderly patients in Argentina, Oliveri et al. found
prevalence between 52% and 87% of vitamin D insufficiency
(serum level below 50 nmol/L) in the winter depending on
the latitude [17]. In another study addressing institutionalized
elderly patients from Buenos Aires, 41% of the residents had
a vitamin D serum level of less than 25 nmol/L [10]. In a
study looking at elderly Italian women, the prevalence of low
vitaminD, defined as a serum level below 30 nmol/L, was 51%
in theDecember–May period and 17% in the June–November
period [18].
5. Vitamin D and the Skeletal Muscle:
Molecular Pathways
Vitamin D receptors (VDR) are expressed in a large number
of human cell types, including skeletalmuscle cells, indicating
the potential for widespread effects [2, 19, 20]. Two mecha-
nisms by which vitamin D may act in skeletal muscle have
been proposed (Figure 1). VDR acts as a nuclear receptor
which mediates the so-called genomic effects; VDR also
acts via nonnuclear receptor mediating nongenomic actions.
Genomic effects have been well characterized in studies in
vitro [8, 21]. VDR is a ligand-dependent transcription fac-
tor, which belongs to the steroid-thyroid hormone receptor
gene superfamily. Once transported in the nucleus by an
intracellular binding protein, calcitriol binds to its nuclear
receptor which results in gene transcription and subsequent
de novo protein synthesis. At the nuclear level, the activation
of VDR induces heterodimerization between the active VDR
and the retinoic receptor (RXR). This leads to the activation
of the vitamin D response element (VDRE), a complex of
genes coding for the “genomic effects” of vitaminD. Genomic
effects of VDR include the increase in calcium handling
by enhancing the activities of the calcium binding protein
(calbindin-D9K) in cell sarcoplasm [22, 23], muscle cell
differentiation and proliferation through effects on insulin
growth factor expression which in turn induces skeletal
muscle hypertrophy [24]. Mechanisms leading to vitamin D
nongenomic effects are not definitely elucidated. 1,25 vitamin
D appears to bind a membrane receptor which activates
a transduction signal inducing MAP kinase (MAPK) and
phospholipase C (PLC) pathways, which in turn lead to a
rapid influx of calcium into the cell [8, 21]. The origin of this
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Figure 1: Effects of 1,25 vitamin D on muscle cells: molecular and nuclear pathways. 1,25 vitamin D binds the vitamin D receptor (VDR) in
the nucleus, where it forms a complex with the retinoid receptor (RXR).The complex 1,25 vitamin D/VDR/XDR activates gene transcription,
leading to known genomic effects. On the other hand, 1,25 vitamin D binds a putative membrane receptor which activates MAP kinase
(MAPK) and phospholipase C (PLC) pathways leading to nongenomic effects.
membrane receptor is controversial. Some authors claimed
that thismembrane receptor is the intranuclearVDR receptor
itself, which translocates from the nucleus to the plasma
membrane, while others suggest that this is a distinct receptor
[25, 26]. Some studies have explored vitamin D molecular
pathways andVDR, through vitaminD supplementation. For
instance, Ceglia et al. showed that, in elderly women, a sup-
plementation of vitamin D (4000 IU/day) during 4 months
was associated with a 30% increase in intramyonuclear VDR
concentration and a 10% increase in muscle fiber cross-
sectional area, especially type 2 fibers [27]. The VDR has
several polymorphisms, some of which may have clinical
significance. Geusens et al. showed that the presence (allele
bb) or absence (allele BB) of a restriction fragment (BsmI)
may determine muscle strength; that is, subjects with the bb
phenotype had 23% higher muscle strength in the quadriceps
than those with the BB phenotype [28].
6. Hypovitaminosis D and Physical
Performance: Observational Studies
Many observational studies have investigated clinical rela-
tionships between vitaminD serum concentration and physi-
cal performance. In the Invecchiare in Chianti (InCHIANTI)
study (966 individuals, 435 men and 531 women) with a
mean age of 75 years, a significant association between
low levels of vitamin D and poor physical performance as
assessed by the handgrip strength test and a short physical
performance battery test (ability to stand from a chair and
ability to maintain balance in progressively more challenging
positions) was found [29]. Individuals with serum vitamin
D below 25 nmol/L performed lower than those with a level
above 25 nmol/L. Muscle strength using a handgrip test was
also significantly greater in subjects with vitamin D levels
higher than 50 nmol/L than in those with levels below this
threshold [29]. Mastaglia et al. reported that, in healthy
women aged over 65 years (𝑛 = 54), vitamin D levels above
50 nmol/L were associated with a higher muscle strength
from lower limbs (stronger knee extensor of 13.4 ± 2.7 versus
11.6 ± 2.5 kg, 𝑃 < 0.03) [30]. Zamboni et al. measured serum
vitamin D in elderly women (𝑛 = 175) and men (𝑛 = 94) and
disability was self-reported using different questionnaires.
Individuals reporting disability had a lower serum vitamin
D level than those without self-reported disability [31]. This
observation was confirmed in the Longitudinal Aging Study
Amsterdam (LASA) prospective study which followed 1200
elderly men and women (600 men and 634 women) during 3
years. A physical assessment was performed at baseline and
after 3 years. Subjects with vitamin D serum levels below
25 nmol/L had a greater chance of showing a decline in
physical performance, defined by a change in the Edwards-
Nunnally Index, than those with levels higher than 75 nmol/L
(OR: 2.21, 95% CI 1.00–4.87) [32]. Using data from the same
cohort, Visser et al. demonstrated that elderly individuals
with a low vitamin D level (<25 nmol/L) had a 2.5-fold
increase in the risk of developing sarcopenia, defined as a loss
of handgrip strength of more than 40% or a loss of muscle
mass ofmore than 3%, in a 3-year time period, comparedwith
those with levels of > 50 nmol/L [33]. In a study investigating
4 BioMed Research International
elderly patients with falls (230men and 370 women), a higher
serum concentration of vitamin D was associated with a
3 times faster “time and get up” (TUG) test (i.e., the time
required for the patient to stand up from a standard chair,
walk a distance of 3 meters, turn around, walk back to the
chair, and sit down again), with a five times faster “sit to
stand” test in men, and with a 2.5 times faster TUG test in
women. The data suggest possible differences in the effects
of vitamin D according to the gender [34]. However, in the
Progetto Veneto Anziani (Pro.V.A) study, which included
2694 community-dwelling elderly patients (1597 females and
1097 males, mean age of 74 years, 40% of women and 20% of
men with a serum vitamin D below 50 nmol/L), it was shown
that lower vitamin D levels were associated with a lower 6-
minute walking test and weaker strength, independently of
gender [35]. Positive effects of vitamin D reserves are not
only observed in older persons. In a study including 1000
healthy European adolescents (470 males and 530 females),
handgrip test performance was positively associated with
vitamin D levels in females [3]. In another study including
young women (age between 19 and 29 years), there was a
correlation between vitamin D level and the handgrip test in
both dominant and nondominant arms [36]. An additional
study in healthy men (𝑛 = 205) and women (𝑛 = 214) (mean
age of 43 years) showed a relationship between vitaminD and
isometric/isokinetic arm strengths in multivariate analysis
[37]. In the particular setting of CKD, 3 small studies, one
study in CKD treated conservatively and 2 studies in dialysis
patients, suggest a positive relationship between vitamin D
status and functional ability [38–40].
A few studies did not confirm an association between
vitamin D status and physical performances. Pramyothin et
al. performed a study in older Hawaii women of Japanese
ancestry, a population known for its very low rate of falls,
a high dietary intake in vitamin D, and a large exposure to
sunlight [41]. In this population, mean vitamin D level was
80 nmol/L and no subject presented vitamin D deficiency.
There was no relationship between vitamin D level, physical
strength test (except for the quadriceps), falls, and daily activ-
ities. The authors conclude that the absence of relationship
was due to the very high level of vitamin D at baseline. In
addition, another study in young men (mean age of 47 years)
from Ceglia et al. including more than 1000 individuals did
not demonstrate a link between vitaminD levels and physical
performances [42]. However, only 20% of the subjects had a
vitamin D level below 50 nmol/L [42]. These 2 negative stud-
ies, along with other observations, suggest the existence of a
threshold in vitamin D level, below which hypovitaminosis
D may negatively affect muscle function [29, 30]. However,
in one study including 367 elderly individuals aged more
than 80 years with 80% prevalence in vitaminD insufficiency,
there was again no relationship between vitamin D level and
physical performance, as assessed by gait speed, hand grip
test, and a static balance test. In this case, the authors explain
the absence of association by the decrease in VDR expression
observed in very old individuals [43].
To sum up, most of the observational studies report
a significant association between hypovitaminosis D and
muscle dysfunction in all categories of ages, except in very
old individuals. On the contrary, vitamin D levels greater
than 50 nmol/L are associated with the lowest probability of
muscle dysfunction. Some studies suggest that gender may
influence the association between vitamin D and skeletal
muscle function.
7. Can Vitamin D Supplementation Improve
Muscle Function?
Several RCTs and meta-analyses have investigated the effect
of vitaminD supplementation onmuscle function. TwoRCTs
in Asians, one in healthy young volunteers [44] and another
one in elderly women, compared the supplementation of
daily or weekly (Table 1) vitamin D combined with calcium
versus calcium alone or placebo [11]. These studies reported
a benefit of vitamin D supplementation during 3 to 6 months
on muscle function, that is, an improvement in quadriceps
strength as measured by an isokinetic dynamometer device
[11] and an improvement in 6minwalk test [44]. Another trial
in 300 elderly women with a level of vitamin D <60 nmol/L
demonstrated a benefit with a daily supplementation of
2000 IU of vitamin D on the TUG test. The subjects from the
lowest quartile had an additional improvement in muscular
strength [45]. Benefits of vitamin D supplementation were
also shown in teenager females. Ward et al. randomized 69
postmenarchal females to receive either 4 doses of 150,000 IU
of vitamin D2 or placebo, over one year. In the interventional
group, mean vitamin D level was greater than 50 nmol/L
and this was associated with improved jump velocity [46].
Another small interventional trial including young elite ballet
dancers (11 males and 13 females, mean age: 28) showed an
improved isometric strength and less injuries in the group
receiving a daily dose of 2000 IU vitamin D [47]. In contrast,
2 trials did not show a benefit of vitamin D supplementation
[48, 49]. However, one of these studies included healthy
men, with very good physical performance at baseline and
without vitamin D deficiency/insufficiency [48]. In the other
study, vitamin D was administrated at a lower dose, that
is, 8400 IU of vitamin D3 once weekly, and this failed to
improve physical performance, but in the latter study, there
was a positive effect on balance in a subgroup of patients
with markedly low balance at baseline [49]. Two additional
RCTs using intermittent large amounts of vitamin D did
not show a benefit on physical performance [50–53]. One
study tested the effect of 150,000 IU of cholecalciferol every 3
months in 689 elderly women (mean age above 76 years) for
9 months. Muscle strength was assessed at baseline and every
3 months with a dynamometer, and mobility was measured
by a TUG test [52]. There was no difference between the
treatment and the control groups. However, vitamin D was
measured in only 40 subjects of the 700 subjects with indeed
a high baseline level (65.8 nmol/L). In the other study, 173
young healthy females (mean age of 21 years) were given a
supplementation of 60,000 IU of cholecalciferol, once a week
for 8 weeks, and then 60,000 IU every 2months for 4months.
Therewas no difference inmuscle strength at 6months.These
findings suggest that intermittent high doses of vitamin D
may not be effective at improving muscular strength. This
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lack of clinical effect may be explained by the inability of high
intermittent doses of vitaminD tomaintain high serum levels
for a sustained period, as suggested by Gupta et al. [44].
The meta-analysis from Muir and Montero-Odasso,
which pooled results from 13 RCTs in individuals older than
60 years old, supported a small benefit of daily vitamin
D supplementation (800 IU to 1000 IU per day) for muscle
strength and balance [54]. However, another meta-analysis
by Stockton et al. looking at 17 RCTs in individuals of all
ages including younger subjects only showed a benefit in
muscle strength in subjects with vitamin D serum levels
below 25 nmol/L at baseline [55].
Whether 1,25 vitamin D is also effective to improve mus-
cle function has been insufficiently investigated. A prospec-
tive uncontrolled trial, not meeting the criteria of our search
but including 2000 elderly subjects (mean age of 75 years,
80% females), showed that a daily supplementation of 1mcg
of alfacalcidol leads to significant improvements of the TUG,
chair rising test, and tandem gait tests, used as surrogates of
muscle performance and risk of fall [56].
Overall, data from RCT and meta-analysis support a
positive effect of daily vitamin D supplementation on muscle
function, especially in older individuals with vitamin D
insufficiency/deficiency at baseline. A daily dose of 1000UI
appears to be sufficient to obtain significant improvements. In
contrast, large intermittent doses of vitamin D do not appear
to be efficient at improving muscle strength.
8. Relationship between Vitamin D Status,
Muscle, and Falls
The known association of vitamin D insufficiency and
increased risk of falls and fractures in the elderly [50, 51, 57–
59] was thought to depend on bone remodeling via the rise of
PTH [60]. However, current understanding has highlighted
the importance of a direct effect of vitamin D on muscle
strength and function [21] to explain this association. Because
vitamin D has an effect on type 2 muscle fibers, it was
tempting to speculate a protective effect of vitamin D on
falls, via improvement in muscle function. A high number of
RCTs have investigated whether vitamin D supplementation
had an effect on muscle function and the incidence of falls.
A Cochrane review published in 2003 [61] evaluated the
efficacy of supplementation with vitamin D analogs, either
alone or with calcium as cosupplementation at preventing
falls. The overall analysis of vitamin D versus control found
no significant difference in the rate of falls when applied
to unselected community-dwelling and hospitalized elderly
subjects (RR 0.87, 95% CI 0.70–1.08). In contrast, in more
recent studies, benefits of vitamin D supplementation were
significant. Pfeifer et al. demonstrated a reduction in falls
of 27 and 39% at one year and 20 months, respectively,
in community-dwelling seniors supplemented with 800 IU
vitamin D and calcium daily versus with calcium only [62].
This reduction in falls was correlated with an improvement
in quadriceps strength and an improvement in the TUG test.
These results are consistent with the study of Bischoff et al.
who showed a 49% reduction of falls in elderly women from
a geriatric ward supplemented with 800 IU per day of vitamin
D [63]. In the same period, results from 3 meta-analyses
demonstrate a significant reduction in the odd ratio of falls
in individuals supplemented with vitamin D [64–66].
Figure 2 shows the effects of vitamin D on muscle func-
tion, gait, and falls. Table 1 summarizes the studies which
investigated the clinical effects of vitamin D on muscle
strength, function, and the risk of falls. The most recent
report of the Endocrine Society Clinical Practice Guidelines
recommends vitamin D supplementation depending on age
and clinical circumstances, in particular in order to prevent
falls in populations at risk [15]. However, a recent paper from
the Institute of Medicine from the United States questioned
the effect of vitamin D supplementation on extraskeletal
outcomes [67], in particular in the setting of falls, arguing that
the meta-analysis of Bischoff-Ferrari et al. provided mislead-
ing conclusions, that is, a vitamin D-associated decrease of
22% in the risk of falls, due to heterogeneity considerations
in the 5 RCTs considered [66].
9. A Link between Vitamin D and Frailty?
The term “frailty” is becoming more and more popular in
geriatric medicine. However, its definition is vague. The
Oxford dictionary defined it by “the condition of being weak
and delicate.” Amore precise definition is given by Fried who
defined frailty as “a biologic syndromeof decrease reserve and
resistance to stressors that results from cumulative declines
across multiple physiologic systems and causes vulnerability
to adverse outcomes [68].” Criteria of the frail phenotype have
been described in order to translate the above theoretical
definition into clinical indicators [68]. These are as follows:
unintentionalweight loss, self-reported exhaustion,weakness
(grip strength), slow walking speed, and low physical activity.
According to these clinical criteria, 3 phenotypes have been
identified: robust: 0 criteria; prefrail: between 1 and 2 criteria;
frail: 3 or more criteria. The majority of these criteria are
related to locomotion and physical strength. Thus, it looks
readily conceivable that hypovitaminosis D may lead to
frailty, through negative effects on muscle strength and/or
function.
The association between vitamin D status and frailty has
been studied in a number of observational studies. Data from
an observational study from Hirani et al. which included
1659 community-dwelling men, with a 10% prevalence of
frailty, showed that low vitamin D levels were independently
associated with frailty [69]. A similar association was found
by Tajar et al. in another cohort of elderly men. Subjects
with vitamin D levels <50 nmol/L had an odd ratio of 2,37 of
being classified into the “frail” versus the “robust” phenotype
[70]. Using data from the thirdNationalHealth andNutrition
Survey (NHANES),Wilhelm-Leen et al. found an association
between frailty and a low vitaminD status in both elderlymen
and women, with overall 4-fold increase in the odd ratio of
frailty [71]. Vitamin D not only is associated with frailty but
also appears to be associatedwith an increased risk to develop
frailty over time in women. In a prospective study including
elderly women (age > 69 years), nonfrail women at baseline
but displaying a vitamin D level of less than 50 nmol/L had
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Figure 2: Clinical effects of vitamin D on muscles gait and falls.
a higher risk of becoming frail during the 4.5 years of follow-
up than women with a higher level of vitamin D [72]. In a
study from patients with cardiac insufficiency, Boxer et al.
found an association between low vitamin D levels and the
frail phenotype. In particular, vitamin D levels and the result
of the 6-minute walking test were correlated [73]. In cardiac
diseases, this functional test is known to predict survival [74].
Thus, low vitamin D is hypothesized to link with mortality in
this setting. A prospective study including 4000 individuals
(1943 men and 2788 women, mean age: 70), followed up
to 12 years, indeed found a link between lower levels of
vitamin D, frailty, and mortality. An assessment of vitamin D
status and the physical phenotype (robust/prefrail/frail) were
performed at baseline [75].
Mortality was positively associated with frailty. Frail
individuals with a low vitamin D level were at increased risk
(hazard ratio of 2.98) of death during the follow-up compared
to robust individuals with a high level of vitamin D. Thus,
overall, a clear association between vitaminD level and frailty
has been demonstrated. Furthermore, interplays between
vitamin D status, frailty, and mortality appear plausible.
Whether vitamin D supplementation in frail subjects may
reduce mortality is challenging and needs to be investigated
in the future.
10. Conclusion
Consistent relationships exist between vitamin D status and
muscle function, especially in the elderly frail patient. There
is evidence that hypovitaminosis D is associated with a
decline in muscle function. Vitamin D supplementation
has beneficial effects on muscle strength, balance, and gait
in diverse settings including adolescents, the elderly, and
CKD patients. However, the effects of vitamin D on the
prevention of falls are still a matter of debate due to con-
flicting interpretation of data. Differences in the dose of
supplementation, type of vitamin D, and discrepancies in the
threshold to define vitamin D deficiency/insufficiency may
partly explain these disagreements. A low vitamin D status is
consistently associated with frailty. Considering that vitamin
D supplementation is safe and inexpensive, it is worthy to
recommend vitaminD supplementation in patients at risk for
falls, such as elderly patients, nursing home residents, frail
patients with gait and balance and visual impairments, and
patients with chronic diseases. These patients are most likely
to have low levels of vitamin D and muscle loss/dysfunction,
thus justifying supplementation independent of a putative
effect on the prevention of falls.
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